Groundbreaking work that Elazer Edelman is doing in endothelium and biomaterials using imaging as endpoint
If you want to know more about CV imaging, follow us and read our articles! @IntJCVImaging#echofirst#yescct#whyCMR
What a great moment to be working in HFpEF specifically and cardiometabolism in general!
Wanna learn how to evaluate HFpEF using imaging? Read our journal @IntJCVImaging#echofirst#yesCCT#whyCMR
Great use of cardiovascular imaging techniques to demonstrate that empagliflozin reduces MI size!
If you want to learn more about cardiac imaging, read our journal @IntJCVImaging
Great editorial comment about the CLEAR Outcomes trial by the world-renown lipid expert @juanbadimon
As we are an imaging journal, this trial could only be better if it also had imaging endpoints!
#whyCMR#yesCCT#echofirst
Everything you wanted to know about the CLEAR-Outcomes trial, but were afraid to ask.
Read my view on the latest @secardiologia blog entry
LDL, the lower the better, the earlier the better!
https://t.co/dteyF3BRRI
@lipidmir@ResiSec#cardioed#meded@Capijorge1
"EMPULSE: en insuficiencia cardiaca aguda, empagliflozina causa mejoría de la congestión temprana, efectiva y sostenida en el tiempo, que se asocia con beneficio clínico a largo plazo", señala @santosgallegoMD. #BlogSEC@jovenesSEC https://t.co/BjnW6mEiNY
With every passing day I learn that @SantosGallegoMD is an expert on another topic (SGLT2i, Spanish wine, opera, Futbol, tapas, bourbon…the list is endless). @rachkataria and @JonathanDavisHF decided that he is the most interesting man in the world. (#AHA22 edition)